Drug intelligence / Profile preview

IgPro10

Development stage
Approved
Lead developer
CSL Behring
Modality
Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

IgPro10 is a highly purified, ready-to-use liquid formulation of human normal immunoglobulin G (IVIG) at a concentration of 10%. It is stabilized with the amino acid L-proline and manufactured from pooled human plasma using octanoic acid fractionation and chromatography. The product undergoes additional isoagglutinin reduction steps to minimize hemolytic risk. IgPro10 acts by providing passive immunity through a broad spectrum of antibodies against various pathogens and modulates immune responses via multiple mechanisms including Fc receptor blockade, complement inhibition, neutralization of autoantibodies, and modulation of cytokine production. It is primarily indicated for primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), immune thrombocytopenia (ITP), Kawasaki disease (KD), myasthenia gravis (MG), and other conditions requiring immunomodulation or antibody replacement[1][3][5][6][8][9][10].

Brand names
Privigen
Other names
intravenous immunoglobulin 10 percentIVIG 10 percentIVIG10 percentIVIG-10 percentpolyclonal immunoglobulin G stabilized with L-proline
02

Targets

NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on IgPro10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgPro10.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call